Project Grant R16AI201138
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $145K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Mt Pleasant, MI 48859, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $516,410 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop precision biomaterials that enrich and monitor antigen-specific immune cells in vivo. The research addresses a critical gap in immunological assessment: current methods for measuring antigen-specific cells require expensive and time-consuming ex vivo expansion that can alter cell...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, awarded The University of Chicago $442,296 on June 9, 2026, to develop selective antiviral RNA-degrading chimeras that directly cleave viral RNA through general acid-general base catalysis, advancing beyond current RNA-degrading chimeras that achieve only approximately 75 percent RNA knockdown. The work targets Zika virus, a mosquito-borne flavivirus associated with severe neurological...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $236,250 on July 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate CG dinucleotide-mediated immune responses during West Nile virus infection. The project examines how peripheral and lymphoid dendritic cells interact with CG-, UA-, and CG/UA-enriched viral variants. The research leverages characterized West Nile virus variants and human peripheral...
- The National Institute of Allergy and Infectious Diseases awarded Ferris State University $132,000 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a metabolic engineering platform for macrolide combinatorial biosynthesis. The funded research addresses antimicrobial resistance by designing and constructing novel biosynthetic pathways that produce new macrolide derivatives with altered hydroxylation and glycosylation patterns. The work...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,600 on May 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate human astrovirus interactions with the intestinal epithelial barrier. The research employs human intestinal organoids derived from stem cells to model how human astroviruses infect and disrupt tight junctions across different regions of the gastrointestinal tract. The work...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $200,000 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate ubiquitin ligase TRIM39 as a host factor controlling Zika virus infection. Northwestern will conduct research identifying and characterizing TRIM39's role in Zika virus (ZIKV) replication and exploring its potential as an anti-viral therapeutic target. Prior high-throughput screening...
- The National Institute of Allergy and Infectious Diseases awarded The University of Akron $538,741 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct structure and function studies of orphan cytochrome P450 enzymes CYP126A1 and CYP143A1 from Mycobacterium tuberculosis. The research will employ resonance Raman spectroscopy and biochemical analysis to define the structural features of reactive intermediates governing CYP126A1 catalysis, elucidate...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Notre Dame $237,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop monoclonal antibody-conjugated nanoparticles for targeted cytomegalovirus antiviral delivery. The project addresses limitations of current CMV therapies—ganciclovir and valganciclovir—which...